Key result
Genetic knockdown of Gnao1 ameliorated cardiac dysfunction and prolonged survival in mouse heart failure models, whereas its overexpression was sufficient to induce cardiac dysfunction.
Why the study?
The molecular mechanisms by which the transcriptional repressor NRSF suppresses the fetal cardiac gene program and maintains cardiac integrity remained to be determined.
The NRSF-regulated Gαo protein plays a critical role in cardiac Ca2+ homeostasis, and its inhibition ameliorates cardiac dysfunction in mouse models of heart failure, highlighting it as a potential therapeutic target.
Background: During the development of heart failure, a fetal cardiac gene program is reactivated and accelerates pathological cardiac remodeling. We previously reported that a transcriptional repressor, NRSF (neuron restrictive silencer factor), suppresses the fetal cardiac gene program, thereby maintaining cardiac integrity. The underlying molecular mechanisms remain to be determined, however. Methods: We aim to elucidate molecular mechanisms by which NRSF maintains normal cardiac function. We generated cardiac-specific NRSF knockout mice and analyzed cardiac gene expression profiles in those mice and mice cardiac-specifically expressing a dominant-negative NRSF mutant. Results: We found that cardiac expression of Gα o , an inhibitory G protein encoded in humans by GNAO1 , is transcriptionally regulated by NRSF and is increased in the ventricles of several mouse models of heart failure. Genetic knockdown of Gnao1 ameliorated the cardiac dysfunction and prolonged survival rates in these mouse heart failure models. Conversely, cardiac-specific overexpression of GNAO1 in mice was sufficient to induce cardiac dysfunction. Mechanistically, we observed that increasing Gα o expression increased surface sarcolemmal L-type Ca 2+ channel activity, activated CaMKII (calcium/calmodulin-dependent kinase-II) signaling, and impaired Ca 2+ handling in ventricular myocytes, which led to cardiac dysfunction. Conclusions: These findings shed light on a novel function of Gα o in the regulation of cardiac Ca 2+ homeostasis and systolic function and suggest Gα o may be an effective therapeutic target for the treatment of heart failure.
No takes yet. Share an insight, caveat, or question.
A 2021 study studied Heart failure. Genetic knockdown or overexpression of Gnao1 vs. Control mice was evaluated on Cardiac dysfunction and survival rates. Genetic knockdown of Gnao1 ameliorated cardiac dysfunction and prolonged survival in mouse heart failure models, whereas its overexpression was sufficient to induce cardiac dysfunction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: